Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK8141-006 | |||
| 2007_587 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Actelion | INDUSTRY |
This study will evaluate the effectiveness and tolerability of MK8141 in lowering blood pressure in patients who have hypertension (high blood pressure).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Arm 1: Drug 250 mg |
|
| 2 | Experimental | Arm 2: Drug 500 mg |
|
| 3 | Active Comparator | Arm 3: Active Comparator |
|
| 4 | Placebo Comparator | Arm 4: Pbo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK8141 | Drug | MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period |
|
| Measure | Description | Time Frame |
|---|---|---|
| To measure the tolerability and effectiveness of MK8141 in lowering 24-hour mean ambulatory blood pressure versus placebo after 4 weeks of treatment. | after 4 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Compare MK8141 versus placebo in lowering 24-hour mean sitting blood pressure by ambulatory blood pressure monitoring and in lowering trough mean sitting diastolic and systolic blood pressure after 4 weeks of treatment. | after 4 weeks of treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20705534 | Result | Jones-Burton C, Rubino J, Roy S, Mai Y, Meehan A, Bellet M, Feig P. Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension. J Am Soc Hypertens. 2010 Sep-Oct;4(5):219-26. doi: 10.1016/j.jash.2010.06.006. Epub 2010 Aug 12. |
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C554657 | MK-8141 |
| D004656 | Enalapril |
| D015773 | Enalaprilat |
| ID | Term |
|---|---|
| D004151 | Dipeptides |
| D009842 | Oligopeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: placebo (unspecified) | Drug | MK8141 Pbo tablet once daily. 4 week treatment period. |
|
| Enalapril | Drug | Enalapril 20 mg tablet once daily. 4 week treatment period. |
|
|